

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

CONTINUING CONNECTED TRANSACTIONS

**EXTENSION OF THE NEW SUBLICENSE AGREEMENT AND THE NEW
PROMOTIONAL SERVICES AGREEMENTS**

**EXTENSION OF THE NEW SUBLICENSE AGREEMENT AND THE NEW
PROMOTIONAL SERVICES AGREEMENTS**

Reference is made to the announcement of the Company dated July 10, 2026 in respect of the New Sublicense Agreement and the New Promotional Services Agreements.

As the parties anticipate that the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements will continue until the end of 2026, on September 28, 2026, Sisram Tianjin and Fosun Wanbang (Jiangsu) agreed to extend the respective terms of the New Sublicense Agreement and the New Promotional Services Agreements to December 31, 2026. The periods covered by their respective maximum transaction amounts for the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements (i.e. from January 1, 2026 to September 30, 2026) will also be extended to December 31, 2026, with such maximum transaction amounts remaining unchanged. Save for the Extension, all other terms of the New Sublicense Agreement and the New Promotional Services Agreements remain unchanged.

LISTING RULES IMPLICATIONS

As at the date of this announcement, Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma and Fosun Pharma is a controlling shareholder of the Company. Therefore, Fosun Wanbang (Jiangsu) is a connected person of the Company. Accordingly, the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements shall be aggregated for the purpose of classification of connected transactions in accordance with Rule 14A.81 of the Listing Rules. As disclosed in the Announcement, the highest applicable percentage ratio in respect of the maximum transaction amounts of the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements on an aggregated basis exceeds 0.1% but is less than 5%. Accordingly, the transactions under the New Sublicense Agreement and the New Promotional Services Agreements are subject to the reporting, annual review and announcement requirements but are exempt from the circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

1. BACKGROUND

Reference is made to the announcement of the Company dated July 10, 2026 (the “**Announcement**”) in respect of the New Sublicense Agreement and the New Promotional Services Agreements entered into between Sisram Tianjin and Fosun Wanbang (Jiangsu), pursuant to which (1) Sisram Tianjin agreed to authorise Fosun Wanbang (Jiangsu) to handle the following aspects of the Product in the Territory, including, among others: (i) import, procurement, customs clearance, legal inspection, warehousing transportation and general distribution; (ii) commercial channel distribution; and (iii) warehousing space, operational procedures, and related systems; and (2) Fosun Wanbang (Jiangsu) agreed to engage Sisram Tianjin to provide promotional services for the Product in the Territory, including, among others, the marketing promotion, academic publicity, formulation and implementation of marketing and commercialization policies. The New Sublicense Agreement and the New Promotional Services Agreements each have a term from September 22, 2025 to September 30, 2026.

Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

2. EXTENSION OF THE NEW SUBLICENSE AGREEMENT AND THE NEW PROMOTIONAL SERVICES AGREEMENTS

As the parties anticipate that the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements will continue until the end of 2026, on September 28, 2026, Sisram Tianjin and Fosun Wanbang (Jiangsu) agreed to extend the respective terms of the New Sublicense Agreement and the New Promotional Services Agreements to December 31, 2026. The periods covered by their respective maximum transaction amounts for the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements (i.e. from January 1, 2026 to September 30, 2026) will also be extended to December 31, 2026, with such maximum transaction amounts remaining unchanged (the “**Extension**”). Save for the Extension, all other terms of the New Sublicense Agreement and the New Promotional Services Agreements remain unchanged.

For the principal terms of the New Sublicense Agreement and the New Promotional Services Agreements, please refer to the Announcement.

3. HISTORICAL TRANSACTION AMOUNTS, MAXIMUM TRANSACTION AMOUNTS AND BASIS

As disclosed in the Announcement, the maximum transaction amounts for the period from January 1, 2026 to September 30, 2026 (which are inclusive of the transactions conducted from January 1, 2026 up to the date of the Announcement) are: (i) US\$2,708,000 in respect of the transactions contemplated under the New Sublicense Agreement; and (ii) US\$3,792,000 in respect of the transactions contemplated under the New Promotional Services Agreements.

For the period from January 1, 2026 to August 31, 2026, the transaction amounts between Sisram Tianjin and Fosun Wanbang (Jiangsu) under the New Sublicense Agreement and the New Promotional Services Agreements were approximately US\$1,380,000 and US\$2,080,000 respectively. As at the date of this announcement, the maximum transaction amounts for the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements have not been exceeded.

Following the Extension, the period covered by the maximum transaction amounts set out above will be extended from September 30, 2026 to December 31, 2026, with such maximum transaction amounts remaining unchanged. The basis on which such maximum transaction amounts were determined remains unchanged. Please refer to the Announcement for further details.

The Board (including the Independent Non-executive Directors) is of the view that, having considered the utilization rate of the maximum transaction amounts as at the date of this announcement and the anticipated transaction volume under the New Sublicense Agreement and the New Promotional Services Agreements for the remainder of 2026, no revision to the maximum transaction amounts is necessary, save that the period covered by such maximum transaction amounts will be extended to December 31, 2026.

4. REASONS FOR AND BENEFITS OF THE EXTENSION

The Extension is primarily intended to align the contractual arrangements with the Group's expected business needs and commercialization timetable for the Product for the remainder of 2026. The Extension will enable the parties to maintain continuity in the import, distribution, marketing promotion and related commercialization arrangements for the Product during the extended period, avoid unnecessary disruption to the established operating arrangements, and allow the Group to continue leveraging the relevant qualifications, distribution network and operational capabilities of Fosun Wanbang (Jiangsu).

The Company is of the view that the Extension is appropriate as it represents only a limited, three-month extension of the respective terms of the New Sublicense Agreement and the New Promotional Services Agreements to December 31, 2026, and does not involve any change to the other terms of such agreements, including the respective maximum transaction amounts. Accordingly, the basis on which the Company formed its views in respect of the New Sublicense Agreement and the New Promotional Services

Agreements as set out in the Announcement remains applicable, and the Company is of the view that the Extension does not affect its assessment of the commercial rationale, fairness and reasonableness of the transactions contemplated thereunder.

Accordingly, the Board (including the Independent Non-executive Directors) is of the view that the Extension is fair and reasonable, on normal commercial terms or better, in the ordinary and usual course of business of the Group and in the interests of the Company and the Shareholders as a whole.

5. LISTING RULES IMPLICATIONS

As at the date of this announcement, Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma and Fosun Pharma is a controlling shareholder of the Company. Therefore, Fosun Wanbang (Jiangsu) is a connected person of the Company. Accordingly, the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements shall be aggregated for the purpose of classification of connected transactions in accordance with Rule 14A.81 of the Listing Rules.

As disclosed in the Announcement, the highest applicable percentage ratio in respect of the maximum transaction amounts of the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements on an aggregated basis exceeds 0.1% but is less than 5%. Accordingly, the transactions under the New Sublicense Agreement and the New Promotional Services Agreements are subject to the reporting, annual review and announcement requirements but are exempt from the circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

Mr. Lior Moshe DAYAN, Mr. Jiahong LI, Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN declared that they also hold certain positions in Fosun Pharma and/or its subsidiaries (other than the Group). According to the Israeli laws and regulations, those Directors are considered to have a personal interest in the New Sublicense Agreement and the New Promotional Services Agreements (including the transactions contemplated thereunder) and are required to abstain from voting on the resolution of the Board approving the Extension. However, the Israeli laws and regulations further provide that, a director may be present at the meeting of the board of directors in relation to a transaction and may participate in the voting if the majority of the directors of the company have a personal interest in such transaction. Accordingly, none of the Directors have abstained from voting on the resolution of the Board approving the Extension.

6. INFORMATION ON THE PARTIES

Information on Fosun Wanbang (Jiangsu)

Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma, the controlling shareholder of the Company. It is mainly engaged in the wholesale of medical drugs.

Information on Sisram Tianjin

Sisram Tianjin is a wholly-owned subsidiary of the Company. The Company is a leading global provider of energy-based medical aesthetic treatment systems, with comprehensive in-house capability to design, develop and produce such systems, which often feature its innovative and proprietary technologies.

7. INTERNAL CONTROLS

The Company has a system to monitor its connected transactions and continuing connected transactions, which includes maintaining and regularly updating the list of connected persons of the Company, checking the contracting party in each transaction to confirm whether it is a connected person, monitoring the value of transactions that are identified as connected transactions against the thresholds for triggering disclosure and shareholder approval requirements under the Listing Rules and ensuring that relevant business departments are regularly updated in relation to the renewal of connected transactions. The Company will implement its internal controls measures and review the measures periodically to ensure applicable Listing Rules requirements will be complied with. Such measures include: (i) the relevant representatives of the Group and its controlling shareholders will meet more regularly to discuss any potential transactions between the Company and its controlling shareholders; (ii) the Company's auditors, Ernst & Young, will review the Group's related party transactions and connected transactions during the audit and financial reporting process, and will report and discuss with the Audit Committee of the Company specifically on these transactions accordingly; (iii) the independent non-executive Directors will perform an annual review on the continuing connected transactions under the New Sublicense Agreement and the New Promotional Services Agreements and confirm in the annual report of the Company that the transactions have been entered into in the ordinary and usual course of business of the Group, on normal commercial terms or better, and according to the agreements governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole; and (iv) the Company will provide additional training on a regular basis to the Directors and the senior management of the Company on the requirements and updates on the regulatory regime regarding connected transactions.

By implementing the above procedures and internal control measures, the Board believes that the Group has established adequate internal control measures to ensure compliance with the maximum transaction amounts and that the Extension and the other terms under the New Sublicense Agreement and the New Promotional Services Agreements would be in line with market terms and normal commercial terms, which are fair and reasonable, and in the interests of the Company and its shareholders as a whole.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, September 28, 2026

As at the date of this announcement, the Board comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purposes only*